Dyne Therapeutics’ (DYN) Buy Rating Reaffirmed at Chardan Capital

Chardan Capital restated their buy rating on shares of Dyne Therapeutics (NASDAQ:DYN) in a report released on Monday morning,Benzinga reports. The firm currently has a $50.00 target price on the stock.

Several other research firms have also issued reports on DYN. Raymond James upgraded Dyne Therapeutics to a “strong-buy” rating in a research note on Thursday, December 12th. Royal Bank of Canada restated an “outperform” rating and set a $45.00 target price on shares of Dyne Therapeutics in a report on Tuesday, January 14th. HC Wainwright decreased their target price on Dyne Therapeutics from $55.00 to $46.00 and set a “buy” rating on the stock in a report on Friday, February 28th. Robert W. Baird started coverage on Dyne Therapeutics in a report on Friday, December 13th. They set an “outperform” rating and a $46.00 target price on the stock. Finally, BMO Capital Markets started coverage on Dyne Therapeutics in a report on Wednesday, March 12th. They set an “outperform” rating and a $50.00 target price on the stock. One research analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Dyne Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $48.85.

Dyne Therapeutics Price Performance

Dyne Therapeutics stock opened at $12.40 on Monday. The stock has a fifty day moving average price of $13.89 and a two-hundred day moving average price of $24.58. Dyne Therapeutics has a 52-week low of $11.18 and a 52-week high of $47.45. The firm has a market capitalization of $1.40 billion, a P/E ratio of -3.48 and a beta of 1.11.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings data on Tuesday, March 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.04. On average, equities research analysts predict that Dyne Therapeutics will post -3.44 EPS for the current fiscal year.

Insider Buying and Selling at Dyne Therapeutics

In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,598 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total value of $36,242.10. Following the transaction, the insider now owns 199,087 shares of the company’s stock, valued at approximately $2,777,263.65. This represents a 1.29 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Over the last quarter, insiders have sold 6,237 shares of company stock valued at $77,760. 20.77% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Dyne Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Quantbot Technologies LP acquired a new position in Dyne Therapeutics in the third quarter valued at about $34,000. Point72 DIFC Ltd acquired a new stake in shares of Dyne Therapeutics during the third quarter worth about $36,000. US Bancorp DE raised its position in shares of Dyne Therapeutics by 776.9% during the third quarter. US Bancorp DE now owns 1,368 shares of the company’s stock worth $49,000 after purchasing an additional 1,212 shares during the period. GF Fund Management CO. LTD. acquired a new stake in shares of Dyne Therapeutics during the fourth quarter worth about $50,000. Finally, KBC Group NV raised its position in shares of Dyne Therapeutics by 53.4% during the third quarter. KBC Group NV now owns 2,157 shares of the company’s stock worth $77,000 after purchasing an additional 751 shares during the period. Institutional investors and hedge funds own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.